25K0
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more
25K0 (25K0) - Total Liabilities
Latest total liabilities as of September 2025: €365.49 Million EUR
Based on the latest financial reports, 25K0 (25K0) has total liabilities worth €365.49 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
25K0 - Total Liabilities Trend (2021–2024)
This chart illustrates how 25K0's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
25K0 Competitors by Total Liabilities
The table below lists competitors of 25K0 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Major-Power Technology Co., Ltd.
TWO:6720
|
Taiwan | NT$279.25 Million |
|
Kofola CeskoSlovensko as
PR:KOFOL
|
Czech Republic | Kč9.06 Billion |
|
GTC
F:G91
|
Germany | €2.01 Billion |
|
Goltas Goller Bolgesi Cimento Sanayi ve Ticaret AS
IS:GOLTS
|
Turkey | TL3.21 Billion |
|
NMPRY
PINK:NMPRY
|
USA | $761.03 Million |
|
Tolu Minerals Ltd
AU:TOK
|
Australia | AU$10.63 Million |
|
COSMO FIRST LIMITED
NSE:COSMOFIRST
|
India | ₹29.75 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down 25K0's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 25K0's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 25K0 (2021–2024)
The table below shows the annual total liabilities of 25K0 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €350.44 Million | -6.96% |
| 2023-12-31 | €376.64 Million | +0.48% |
| 2022-12-31 | €374.83 Million | -2.64% |
| 2021-12-31 | €384.98 Million | -- |